My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 282

    1.

    The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

    Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF.

    Diabetes. 2002 Mar;51(3):797-802.PMID: 11872682 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.

    Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI.

    N Engl J Med. 2004 Feb 12;350(7):664-71.PMID: 14960743 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

    Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM.

    Obes Res. 2002 Oct;10(10):1008-15. Erratum in: Obes Res. 2002 Nov;10(11):following table of contents.. PMID: 12376581 [PubMed - indexed for MEDLINE]Related articles

    5.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.

    Oakes ND, Thalén PG, Jacinto SM, Ljung B.

    Diabetes. 2001 May;50(5):1158-65.PMID: 11334421 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.

    Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein DH, Smith SA, Cobitz AR, Sarkar SK.

    Metabolism. 2003 Feb;52(2):218-25.PMID: 12601636 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.

    Diabetologia. 2001 Dec;44(12):2210-9.PMID: 11793023 [PubMed - indexed for MEDLINE]Related articles

    11.

    Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.

    Racette SB, Davis AO, McGill JB, Klein S.

    Metabolism. 2002 Feb;51(2):169-74.PMID: 11833043 [PubMed - indexed for MEDLINE]Related articles

    12.

    Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.

    Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI.

    Diabetes. 2003 Jun;52(6):1311-8.PMID: 12765938 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

    Diabetes. 2002 Dec;51(12):3479-85.PMID: 12453903 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans.

    Stoll D, Binnert C, Mooser V, Tappy L.

    Metabolism. 2004 Jan;53(1):4-10.PMID: 14681834 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.

    Boden G, Cheung P, Mozzoli M, Fried SK.

    Metabolism. 2003 Jun;52(6):753-9.PMID: 12800103 [PubMed - indexed for MEDLINE]Related articles

    16.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

    Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, Nuutila P.

    Diabetes. 2003 Feb;52(2):283-90.PMID: 12540598 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.

    Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ.

    Metabolism. 2003 Aug;52(8):1078-83.PMID: 12898477 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

    Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

    Tan GD, Fielding BA, Currie JM, Humphreys SM, Désage M, Frayn KN, Laville M, Vidal H, Karpe F.

    Diabetologia. 2005 Jan;48(1):83-95. Epub 2004 Dec 24.PMID: 15619071 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity